Denali Therapeutics Inc Net Income per Employee (DNLI), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Denali Therapeutics Inc   (NASDAQ: DNLI)
 

Denali Therapeutics Inc Net Income per Employee

DNLI's Quarterly Results, Trends, Rankings, Statistics
Denali Therapeutics Inc 's Income per employee grew in the third quarter 2026 on a trailing twelve month basis to $ 393,668, the income was higher than average, indicating higher productivity of the company's employees.
The Healthcare sector has seen employees of 22 other companies achieving higher income per employee. While Denali Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2065 to 2094.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DNLI Net Income per Employee (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Net Income Change - - - 24.66 % -
Net Income per Employee (TTM) $ 393,668 1,962 8,789 -203 -151,171
DNLI's Total Ranking # 2094 # 2065 # 1879 # 2900 #
Seq. Net Income Change - - - - -

DNLI Company Profile >> Back to DNLI Efficiency Comparisons >> Compare DNLI Net Income per Employee to its Competitors

DNLI Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 187
Overall Market # 2094

Net Income per Employee Statistics
High Average Low
$ 656,268 $ -158,026 $ -1,005,767
(Sep 30 2023)   (Dec 31 2021)




  News about Denali Therapeutics Inc Income per employee

Navigating New Frontiers in Rare Disease and Neurodegeneration Denali Therapeutics’ Pivotal Milestones

Denali Therapeutics’ Recent Announcements: Key Facts and Implications Denali Therapeutics Inc., a cutting-edge biopharmaceutical company, is making significant strides in addressing complex and rare diseases through innovative therapeutic approaches. Recent press releases from the company detail two crucial developments: the extension of the FDA review timeline for the Biologics License Application (BLA) for tividenofusp alfa, a promising treatment for mucopolysaccharidosis type II (MPS II), and the initiation of a Phase 2a clinical study of the LRRK2 inhibitor BIIB122 (DNL151) for LRRK2-associated Parkinson s disease (LRRK2-PD). Key Developments: 1. FDA Review Extension for Tividenofusp Alfa: - On October 13, 2025, Denali Therapeutics announced that the FDA extended the review timeline for its BLA seeking accelerated approval of tividenofusp alfa from January 5, 2026, to April 5, 2026. This extension reflects the agency’s need for additional time to assess the data supporting the application for this treatment of Hunter syndrome, a rare lysosomal storage disorder characterized by progressive morbidity.




Companies with similar Income per Employee for 12 month ending Sep 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2026Number of Employees Sep 30 2026
Black Hawk Acquisition Corporation  649,852.50 $ 1.300  Million 2 
Eli Lilly And Company  551,594.00 $ 27,579.700  Million 50,000 
Indivior Pharmaceuticals Inc   451,000.00 $ 451.000  Million 1,000 
Denali Therapeutics Inc   393,667.99 $ 198.015  Million 503 
Neurocrine Biosciences Inc   351,250.00 $ 702.500  Million 2,000 
Standard Biotools Inc   342,097.69 $ 133.076  Million 389 
Regeneron Pharmaceuticals Inc   312,615.18 $ 4,817.400  Million 15,410 
Kiniksa Pharmaceuticals International Plc  299,366.12 $ 109.568  Million 366 
Bristol myers Squibb Company  284,338.46 $ 9,241.000  Million 32,500 
Corcept Therapeutics Inc  221,410.96 $ 161.630  Million 730 


Date modified: 2026-11-04T16:54:19+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.